Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. [electronic resource]
Producer: 20120312Description: 948-55 p. digitalISSN:- 1538-3598
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Arteriovenous Malformations -- etiology
- Bevacizumab
- Cardiac Output -- drug effects
- Epistaxis -- etiology
- Female
- Heart Failure
- Humans
- Liver -- blood supply
- Male
- Middle Aged
- Prospective Studies
- Telangiectasia, Hereditary Hemorrhagic -- complications
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.